Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 1800 Orleans Street, Bloomberg Children's Center, Suite 12344, Baltimore, MD 21287, USA.
Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 1800 Orleans Street, Bloomberg Children's Center, Suite 12344, Baltimore, MD 21287, USA.
Child Adolesc Psychiatr Clin N Am. 2020 Jan;29(1):183-210. doi: 10.1016/j.chc.2019.08.009. Epub 2019 Oct 11.
An increasing number of antipsychotic medications have demonstrated efficacy in randomized placebo-controlled trials in the treatment of children and adolescents with schizophrenia. This review summarizes and synthesizes relevant antipsychotic medication studies, with particular emphasis on second-generation agents, and discusses other clinical considerations that may influence medication selection. With the exception of clozapine demonstrating superior efficacy in the improvement of psychotic symptoms in treatment-resistant patients, many antipsychotic agents have been shown to be similarly efficacious, including first-generation medications. Consideration of the side-effect profile, which can differ substantially from medication to medication, is essential when choosing treatment options.
越来越多的抗精神病药物在儿童和青少年精神分裂症的随机安慰剂对照试验中已被证明具有疗效。本综述总结和综合了相关的抗精神病药物研究，特别强调第二代药物，并讨论了可能影响药物选择的其他临床注意事项。除了氯氮平在改善治疗抵抗患者的精神病症状方面表现出更好的疗效外，许多抗精神病药物已被证明同样有效，包括第一代药物。在选择治疗方案时，必须考虑药物之间可能存在显著差异的副作用特征。
